(0.12%) 5 303.27 points
(0.34%) 40 004 points
(-0.07%) 16 686 points
(0.97%) $80.00
(5.73%) $2.64
(1.44%) $2 419.80
(6.36%) $31.78
(2.18%) $1 094.70
(-0.02%) $0.920
(-0.18%) $10.68
(-0.27%) $0.787
(0.19%) $91.05
@ $8.70
Issued: 13 Feb 2024 @ 09:30
Return: -58.05%
Previous signal: Feb 8 - 14:06
Previous signal:
Return: -7.25 %
Live Chart Being Loaded With Signals
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types...
Stats | |
---|---|
Today's Volume | 51 709.00 |
Average Volume | 128 887 |
Market Cap | 98.54M |
EPS | $-0.253 ( 2024-04-02 ) |
Next earnings date | ( $-0.210 ) 2024-07-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.97 |
ATR14 | $0.0160 (0.44%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-13 | Szalay Aladar | Sell | 3 446 | Common Stock |
2024-05-14 | Szalay Aladar | Sell | 15 426 | Common Stock |
2024-05-15 | Szalay Aladar | Sell | 17 094 | Common Stock |
2024-05-07 | Szalay Aladar | Sell | 6 025 | Common Stock |
2024-05-08 | Szalay Aladar | Sell | 13 919 | Common Stock |
INSIDER POWER |
---|
-16.49 |
Last 100 transactions |
Buy: 714 938 | Sell: 857 974 |
Volume Correlation
Genelux Corporation Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Genelux Corporation Correlation - Currency/Commodity
Genelux Corporation Financials
Annual | 2023 |
Revenue: | $170 000 |
Gross Profit: | $-848 000 (-498.82 %) |
EPS: | $-1.160 |
FY | 2023 |
Revenue: | $170 000 |
Gross Profit: | $-848 000 (-498.82 %) |
EPS: | $-1.160 |
FY | 2022 |
Revenue: | $11.07M |
Gross Profit: | $10.10M (91.25 %) |
EPS: | $-0.210 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Genelux Corporation
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators